{"id":"W2794845062","doi":"10.1016/j.jaad.2018.03.037","title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":188,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Interleukin 17; Randomized controlled trial; Gastroenterology; Clinical trial; Interleukin; Surgery; Immunology; Inflammation; Cytokine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005440579,0.0003273484,0.002250679,0.0004659931,0.00008268491,0.00001259943,0.0003893328,0.0002404921,0.00002867935],"category_scores_gemma":[0.0001789346,0.0001828154,0.0002507655,0.0003362251,0.001616945,0.0002031452,0.00008076509,0.0004347615,0.00000223732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005345377,"about_ca_system_score_gemma":0.0001492544,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003531924,"about_ca_topic_score_gemma":0.0001130444,"domain_scores_codex":[0.9961858,0.001401245,0.001626763,0.0002947935,0.0001501065,0.0003412293],"domain_scores_gemma":[0.9948557,0.0009432052,0.003800808,0.0002064413,0.0001442577,0.00004959207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9868425,0.0009631937,0.004330496,0.00001059199,0.002207164,0.00001061785,0.001534397,0.00001143828,0.001779298,0.00006292588,0.0004916923,0.001755689],"study_design_scores_gemma":[0.9665935,0.004012471,0.003711891,0.0002083194,0.001212596,0.0002898764,0.0004161253,0.00001424712,0.02299742,0.00008171666,0.0002713794,0.0001904296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964531,0.000404734,0.00007955261,0.001332567,0.0003577931,0.001194139,0.00009177059,0.000009221761,0.00007713516],"genre_scores_gemma":[0.9991378,0.0001399909,0.0003323417,0.0001811336,0.00007883308,0.00003230765,0.0000241588,0.00002379933,0.00004966778],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02121812,"threshold_uncertainty_score":0.7454994,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02089051072143032,"score_gpt":0.2762123065281997,"score_spread":0.2553217958067694,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}